United States-based Merck's HIV Therapy Delstrigo (doravirine / lamivudine / tenofovir disoproxil fumarate) has achieved primary efficacy endpoint in phase three Drive-Shift study that is evaluating to convert to Delstrigo from other antiretroviral treatment regimens, it was reported on Friday.
The company has released the first presentation of data from the Phase 3 DRIVE-SHIFT trial assessing a switch of medication to Delstrigo, a once-daily fixed-dose combination tablet of doravirine (100mg), lamivudine (3TC, 300mg) and tenofovir disoproxil fumarate (TDF, 300mg), in adults with HIV-1 infection who showcased virological suppression for around six months on a stable antiretroviral treatment regimen.
The study met its primary endpoint of non-inferior efficacy as measured by the proportion of participants who switched to DELSTRIGO and had plasma HIV-1 RNA levels
genedrive secures initial overseas orders for Genedrive MT-RNR1 ID kit
Kromek collaborates on next-gen CT detector technology
Gilead Sciences initiates Phase 2 trial in Europe to evaluate lenacapavir for HIV prevention
European Commission grants authorisation to ViiV Healthcare's Apretude for prevention of HIV
Celanese to supply VitalDose drug delivery platform for Population Council's MPT Intravaginal Ring
Henry Schein introduces equipment repair subscription - Henry Schein Thrive Service Plus
Seres Therapeutics provides business updates and reports Q2 2023 financial results